2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Palliative Care, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Bacterial, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

3363 Concomitant beta-blocker use is associated with increased relapse and inferior survival in adults with acute myeloid leukemia receiving first-line therapy

Bao Duy An Hoang, BS, Jerry Yuen, BS2, Amy Song, BS3, Julia M. Anderson, BS, MS4, Yazan F. Madanat, MD5, Vivian Irizarry Gatell, MD6, Clayton Jackson, MD7, Stephen Chung, MD8
1 University of Texas Southwestern Medical Center, Dallas, Texas, United States
2 University of Texas Southwestern Medical Center, Dallas, Texas, United States
3 University of Texas Southwestern Medical Center, Dallas, Texas, United States
4 University of Texas Southwestern Medical Center, Dallas, Texas, United States
5 University of Texas Southwestern Medical Center, Dallas, Texas, United States
6 University of Texas Southwestern Medical Center, Dallas, Texas, United States
7 University of Texas Southwestern Medical Center, Dallas, Texas, United States
8 University of Texas Southwestern Medical Center, Dallas, Texas, United States

Introduction: Beta-blockers (BB) are among the most prescribed medications in older adults, the population in which acute myeloid leukemia (AML) incidence is highest. Prior retrospective studies evaluating BB use in patients with solid tumors receiving chemotherapy have reported mixed associations with clinical outcomes. Recovery of normal hematopoiesis is critical following AML therapy. Additionally, recent preclinical data suggest that beta-adrenergic blockade may impair hematopoietic regeneration after transplantation. However, the association between concomitant BB use and outcomes in patients receiving AML therapy has not been well studied.

Objective: We evaluated the association between BB use and clinical outcomes following first-line AML therapy and whether this association varied across ELN 2022 risk groups.

Methods: We conducted a retrospective cohort study of 327 adult patients with AML treated at University of Texas Southwestern Medical Center from 2009 to 2026. Patients were classified according to concomitant systemic BB exposure during first-line induction therapy. For intensive chemotherapy, BB exposure was defined as BB use initiated before or within 3 days after initiation. For lower-intensity regimens, BB exposure was defined as BB use initiated before or within 10 days after initiation, and BB use was continuing for at least one treatment cycle. Intensive regimens included 7+3 and other intensive chemotherapy, whereas lower-intensity induction regimens included venetoclax/azacitidine and hypomethylating-agent monotherapy. Clinical outcomes included overall survival (OS) measured from induction to death from any cause and relapse-free survival (RFS) from induction to refractory disease, relapse, or death from any cause. Cumulative incidence of relapse was analyzed with Gray's test. Baseline comorbidities were defined using the Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI), and disease risk was assigned according to ELN 2022 criteria (55 favorable, 75 intermediate, and 197 adverse). OS and RFS were evaluated using Kaplan-Meier methods. Multivariable Cox proportional hazards models were used to evaluate associations between BB use and outcomes, adjusted for ELN 2022 risk, age, sex, first-line treatment regimen, transplant, and HCT-CI. Associations between BB use and outcomes across ELN 2022 risk groups were assessed using subgroup analyses adjusted for the same covariates and formal interaction testing.

Results: In 415 screened patients, 327 met inclusion criteria for the analysis, and median follow-up was 44 months. BB users were significantly older (median age of 68.5 vs 63 years). HCT-CI was not independently associated with RFS (p=0.92) or OS (p=0.19). Patients receiving BB had shorter median RFS than those not receiving BB (7.93 vs 23.13 months, p<0.001) and shorter median OS (15.3 vs 76.9 months, p<0.001). In adjusted Cox models, BB use remained associated with inferior RFS (adjusted HR [aHR] 1.78, 95% CI 1.32–2.39, p<0.001) and OS (aHR 2.02, 95% CI 1.45–2.83, p<0.001). The cumulative incidence of relapse was higher among BB users (Gray’s test, p=0.0015), whereas non-relapse mortality did not differ significantly between groups (p=0.11). On Kaplan-Meier analysis stratified by ELN 2022 risk, BB use was associated with shorter RFS in the intermediate-risk group (9.83 vs 47.23 months, p<0.001) and adverse-risk group (5.98 vs 14.57 months, p=0.0017). In adjusted subgroup analyses, BB use remained associated with inferior RFS in the intermediate-risk (aHR 2.88, p=0.01) and adverse-risk (aHR 1.78, p=0.0015) groups. However, there was no significant interaction between BB use and ELN 2022 risk for either RFS (p-interaction=0.887) or OS (p-interaction=0.211).

Conclusion: In this retrospective cohort of AML patients receiving first-line induction therapy, BB exposure during treatment was independently associated with inferior RFS and OS. The association with lower RFS persisted within the intermediate- and adverse-risk ELN 2022 subgroups. BB exposure was also associated with higher relapse incidence without a significant difference in non-relapse mortality. These findings suggest that concomitant BB use during induction therapy could be a clinically relevant factor associated with increased relapse risk and shorter survival in AML. Further studies are needed to determine whether beta-adrenergic signaling contributes to relapse after treatment and whether the association is causal.

Bao Duy An Hoang, BS: No relevant conflicts of interest to declare.